Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Supernus Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SUPN
Nasdaq
2834
https://www.supernus.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Apr 24th, 2024 8:05 pm
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
- Apr 8th, 2024 4:11 pm
Supernus Provides Regulatory Update for SPN-830
- Apr 8th, 2024 12:00 pm
Supernus to Participate in Two Upcoming Investor Conferences
- Mar 6th, 2024 9:30 pm
11 Best Small Cap Pharma Stocks to Invest In
- Mar 5th, 2024 1:28 am
Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
- Feb 29th, 2024 11:39 am
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Feb 28th, 2024 9:30 pm
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 2:19 pm
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
- Feb 28th, 2024 12:17 pm
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
- Feb 28th, 2024 12:30 am
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
- Feb 27th, 2024 11:50 pm
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
- Feb 27th, 2024 10:00 pm
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Feb 27th, 2024 9:05 pm
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- Feb 26th, 2024 2:15 pm
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
- Feb 20th, 2024 3:00 pm
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
- Feb 13th, 2024 9:05 pm
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
- Feb 5th, 2024 1:30 pm
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
- Jan 14th, 2024 12:36 pm
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
- Dec 19th, 2023 12:30 pm
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
- Dec 15th, 2023 12:43 am
Scroll